James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Biotech Stocks: Is It Safe to Come out Now? (IBB, XBI)

Biotech stocks are getting smashed this week, but betting against the sector remains a bad idea. The only trick is getting the timing right.

Why Mosaic Co (MOS), ConAgra Foods Inc. (CAG) and Petroleo Brasileiro SA (PBR) Are 3 of Today’s Worst Stocks

Mosaic (MOS), ConAgra Foods (CAG) and Petroleo Brasileiro (PBR) couldn't win for losing on Tuesday. Here's what investors need to know.

Is the Post-Earnings Plunge an Opportunity to Buy CCL Stock?

CCL stock has been roughed up after a disappointing Q4 outlook from Carnival, but you may want to take a closer look at the bigger picture.

4 Things That Could Prevent the S&P 500 From Reaching 2,100

The S&P 500 may well reach the 2015 target Goldman Sachs set for it today. If it does though, it's going to take a miracle and a whole lot of blind investors.

Why Alibaba Group Holding Ltd (BABA), Merck & Co., Inc. (MRK) and BioMarin Pharmaceutical Inc. (BMRN) Are 3 of Today’s Worst Stocks

Monday proved to be less-than-compelling for owners of Alibaba Group (BABA), Merck (MRK) and BioMarin Pharmaceutical (BMRN).